Evidence map›Paper›PMID 27329582›Full record

ArticleScientific reports2016

Prevention and Treatment of Lower Limb Deep Vein Thrombosis after Radiofrequency Catheter Ablation: Results of a Prospective active controlled Study.

Lan Li, Bao-Jian Zhang, Bao-Ku Zhang, Jun Ma, Xu-Zheng Liu, Shu-Bin Jiang

Open access · goldAbstract readComparative StudyControlled Clinical Trial
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Prevention of venous thromboembolism in right heart-sided electrophysiological procedures: results of an European Heart Rhythm Association survey.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lan LiCoronary care unit, Affiliated hospital of Traditional Chinese Medicine, Xinjiang Medical University, 116 Huanghe Rd, Shayibake District, Urumuqi 830000, China.
Bao-Jian ZhangCoronary care unit, Affiliated hospital of Traditional Chinese Medicine, Xinjiang Medical University, 116 Huanghe Rd, Shayibake District, Urumuqi 830000, China.
Bao-Ku ZhangCoronary care unit, Affiliated hospital of Traditional Chinese Medicine, Xinjiang Medical University, 116 Huanghe Rd, Shayibake District, Urumuqi 830000, China.
Jun MaCoronary care unit, Affiliated hospital of Traditional Chinese Medicine, Xinjiang Medical University, 116 Huanghe Rd, Shayibake District, Urumuqi 830000, China.
Xu-Zheng LiuCoronary care unit, Affiliated hospital of Traditional Chinese Medicine, Xinjiang Medical University, 116 Huanghe Rd, Shayibake District, Urumuqi 830000, China.
Shu-Bin JiangCoronary care unit, Affiliated hospital of Traditional Chinese Medicine, Xinjiang Medical University, 116 Huanghe Rd, Shayibake District, Urumuqi 830000, China.
Xinjiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We conducted a prospective, single-center, active controlled study from July 2013 to January 2015, in Chinese patients with rapid ventricular arrhythmia who had received radiofrequency catheter ablation (RFCA) treatment to determine formation of lower extremity deep vein thrombosis (LDVT) post RFCA procedure, and evaluated the effect of rivaroxaban on LDVT. Patients with asymptomatic pulmonary thromboembolism who had not received any other anticoagulant and had received no more than 36 hours of treatment with unfractionated heparin were included. Post RFCA procedure, patients received either rivaroxaban (10 mg/d for 14 days beginning 2-3 hours post-operation; n = 86) or aspirin (100 mg/d for 3 months beginning 2-3 hours post-operation; n = 90). The primary outcome was a composite of LDVT occurrence, change in diameter of femoral veins, and safety outcomes that were analyzed based on major or minor bleeding events. In addition, blood flow velocity was determined. No complete occlusive thrombus or bleeding events were reported with either of the group. The lower incidence rate of non-occluded thrombus in rivaroxaban (5.8%) compared to the aspirin group (16.7%) indicates rivaroxaban may be administered post-RFCA to prevent and treat femoral venous thrombosis in a secure and effective way with a faster inset of action than standard aspirin therapy.

Indexed as

Femoral VeinAdolescentAdultAgedAged, 80 and overArrhythmias, CardiacAspirinCatheter AblationChinaFemaleHumansLower ExtremityMaleMiddle AgedProspective StudiesRivaroxabanAspirinRivaroxaban

Identifiers

PMID27329582
PMCPMC4916462
OpenAlexW2471248133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.